Cutaneous lupus erythematosus: Issues in diagnosis and treatment

American Journal of Clinical Dermatology

Volumn 10, Issue 6, 2009, Pages 365-381

  Walling, Hobart ^a   Sontheimer, Richard ^b  

^a Private Practice of Dermatology   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALPHA INTERFERON; AMFEBUTAMONE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CAPTOPRIL; CORTICOSTEROID; DAPSONE; DILTIAZEM; DOCETAXEL; EFALIZUMAB; GLIBENCLAMIDE; GRISEOFULVIN; HYDROCHLOROTHIAZIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LEFLUNOMIDE; METHOTREXATE; NAPROXEN; NIFEDIPINE; OMEPRAZOLE; PHENYTOIN; PIROXICAM; RETINOID DERIVATIVE; RO ANTIBODY; TAMOXIFEN; TERBINAFINE; TETRACYCLINE; THALIDOMIDE; UNINDEXED DRUG;

ACUTE DISEASE; ALOPECIA; BLISTER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHRONIC DISEASE; CLINICAL FEATURE; CONSTIPATION; DISEASE ASSOCIATION; DISEASE COURSE; FERTILITY; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGIC SKIN REACTION; HUMAN; HYPERCOAGULABILITY; IMMUNOPATHOLOGY; LABORATORY TEST; LIVEDO RETICULARIS; LIVER TOXICITY; LUNG FIBROSIS; NEPHROTOXICITY; PANCREATITIS; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTECTIVE CLOTHING; RAYNAUD PHENOMENON; RETINOPATHY; REVIEW; SECONDARY AMENORRHEA; SEDATION; SEROLOGY; SIDE EFFECT; SKIN LUPUS ERYTHEMATOSUS; SKIN PIGMENTATION; SKIN SCAR; SYSTEMIC LUPUS ERYTHEMATOSUS; TELANGIECTASIA; TERATOGENICITY; VASCULITIS; XERODERMA;

HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, DISCOID; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 70350331320     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11310780-000000000-00000     Document Type: Review

References (139)

1. Costner MI, Sontheimer RD, Provost TT. Lupus erythematosus. In: Sontheimer RD, Provost TT, editors. Cutaneous manifestations of rheumatic diseases. 2nd ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2004: 15-64
2. Kuhn A, Sontheimer RD, Ruzicka T. Clinical manifestations of cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T, editors. Cutaneous lupus erythematosus. Chapter 6. Heidelberg: Springer Verlag, 2005: 59-92
3. Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol 2006 Sep-Oct; 24 (5): 348-362 (Pubitemid 44332871)
4. Font J, Cervera R, Ramos-Casals M, et al. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum 2004 Feb; 33 (4): 217-230
5. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006 Aug; 54 (8): 2550-2557
6. Vitali C, Doria A, Tincani A, et al. International survey on the management of patients with SLE: I. General data on the participating centers and the results of a questionnaire regarding mucocutaneous involvement. Clin Exp Rheumatol 1996 Nov-Dec; 14 Suppl. 16: S17-22
7. Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993 Mar; 72 (2): 113-124
8. Sontheimer RD. Subacute cutaneous lupus erythematosus. Clin Dermatol 1985 Jul-Sep; 3 (3): 58-68
9. Bielsa I, Herrero C, Font J, et al. Lupus erythematosus and toxic epidermal necrolysis. J Am Acad Dermatol 1987 Jun; 16 (6): 1265-1267
10. DeSpain J, Clark DP. Subacute cutaneous lupus erythematosus presenting as erythroderma. J Am Acad Dermatol 1988 Aug; 19 (2 Pt 2): 388-392
11. Scheinman PL. Acral subacute cutaneous lupus erythematosus: an unusual variant. J Am Acad Dermatol 1994 May; 30 (5 Pt 1): 800-801
12. Sontheimer RD, Maddison PJ, Reichlin M, et al. Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med 1982 Nov; 97 (5): 664-671
13. Mond CB, Peterson MG, Rothfield NF. Correlation of anti-Ro antibody with photosensitivity rash in systemic lupus erythematosus patients. Arthritis Rheum 1989 Feb; 32 (2): 202-204
14. Sarzi-Puttini P, Atzeni F, Capsoni F, et al. Drug-induced lupus erythematosus. Autoimmunity 2005 Nov; 38 (7): 507-518
15. Vasoo S. Drug-induced lupus: an update. Lupus 2006; 15 (11): 757-761
16. Vedove CD, Del Giglio M, Schena D, et al. Drug-induced lupus erythematosus. Arch Dermatol Res 2009 Jan; 301 (1): 99-105
17. Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patientoriented translational clinical investigation. Arch Dermatol Res 2009 Jan; 301 (1): 65-70
18. De Berker D, Dissaneyeka M, Burge S. The sequelae of chronic cutaneous lupus erythematosus. Lupus 1992 May; 1 (3): 181-186
19. Wilson CL, Burge SM, Dean D, et al. Scarring alopecia in discoid lupus erythematosus. Br J Dermatol 1992 Apr; 126 (4): 307-314
20. Tebbe B, Mansmann U, Wollina U, et al. Markers in cutaneous lupus erythematosus indicating systemic involvement: a multicenter study on 96 patients. Acta Derm Venereol 1997 Jul; 77 (4): 305-308
21. Ueki H. Koebner phenomenon in lupus erythematosus with special consideration of clinical findings. Autoimmun Rev 2005 Apr; 4 (4): 219-223
22. Daldon PE, Macedo de Souza E, Cintra ML. Hypertrophic lupus erythematosus: a clinicopathological study of 14 cases. J Cutan Pathol 2003 Aug; 30 (7): 443-448
23. Uitto J, Santa-Cruz DJ, Eisen AZ, et al. Verrucous lesion in patients with discoid lupus erythematosus: clinical, histopathological and immunofluorescence studies. Br J Dermatol 1978 May; 98 (5): 507-520
24. Ahmed AR, Schreiber P, Abramovits W, et al. Coexistence of lichen planus and systemic lupus erythematosus. J Am Acad Dermatol 1982 Oct; 7 (4): 478-483
25. Massone C, Kodama K, Salmhofer W, et al. Lupus erythematosus panniculitis (lupus profundus): clinical, histopathological, and molecular analysis of nine cases. J Cutan Pathol 2005 Jul; 32 (6): 396-404
26. Carducci M, Mussi A, Lisi S, et al. Lupus mastitis: a 2-year history of a single localization of lupus erythematosus mimicking breast carcinoma. J Eur Acad Dermatol Venereol 2005 Mar; 19 (2): 260-262
27. Ruiz H, Sá nchez JL. Tumid lupus erythematosus. Am J Dermatopathol 1999 Aug; 21 (4): 356-360
28. Rémy-Leroux V, Lé onard F, Lambert D, et al. Comparison of histopathologic- clinical characteristics of Jessner's lymphocytic infiltration of the skin and lupus erythematosus tumidus: multicenter study of 46 cases. J Am Acad Dermatol 2008 Feb; 58 (2): 217-223
29. Kuhn A, Sonntag M, Richter-Hintz D, et al. Phototesting in lupus erythematosus tumidus: review of 60 patients. Photochem Photobiol 2001 May; 73 (5): 532-536
30. Yell JA,Mbuagbaw J, Burge SM. Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 1996 Sep; 135 (3): 355-362
31. Hedrich CM, Fiebig B, Hauck FH, et al. Chilblain lupus erythematosus: a review of literature. Clin Rheumatol 2008 Aug; 27 (8): 949-954
32. Rice G, Newman WG, Dean J, et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am J Hum Genet 2007 Apr; 80 (4): 811-815
33. Ló pez-Labady J, Villarroel-Dorrego M, Gonzá lez N, et al. Oral manifestations of systemic and cutaneous lupus erythematosus in a Venezuelan population. J Oral Pathol Med 2007 Oct; 36 (9): 524-527
34. Lourenço SV, de Carvalho FR, Boggio P, et al. Lupus erythematosus: clinical and histopathological study of oral manifestations and immunohistochemical profile of the inflammatory infiltrate. J Cutan Pathol 2007 Jul; 34 (7): 558-564
35. Nico MM, Vilela MA, Rivitti EA, et al. Oral lesions in lupus erythematosus: correlation with cutaneous lesions. Eur J Dermatol 2008 Jul-Aug; 18 (4): 376-381
36. Lee LA. Neonatal lupus: clinical features and management. Pediatr Drugs 2004; 6 (2): 71-78
37. Weston WL, Morelli JG, Lee LA. The clinical spectrum of anti-Ro-positive cutaneous neonatal lupus erythematosus. J Am Acad Dermatol 1999 May; 40 (5 Pt 1): 675-681
38. Boh EE. Neonatal lupus erythematosus. Clin Dermatol 2004; 22 (2): 125-128
39. Martin V, Lee LA, Askanase AD, et al. Long-term followup of children with neonatal lupus and their unaffected siblings. Arthritis Rheum 2002; 46 (9): 2377-2383
40. Dhar JP, Essenmacher LM, Ager JW, et al. Pregnancy outcomes before and after a diagnosis of systemic lupus erythematosus. Am J Obstet Gynecol 2005 Oct; 193 (4): 1444-1455
41. Molad Y. Systemic lupus erythematosus and pregnancy. Curr Opin Obstet Gynecol 2006 Dec; 18 (6): 613-617
42. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725
43. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982 Nov; 25 (11): 1271-1277
44. Tebbe B. Clinical course and prognosis of cutaneous lupus erythematosus. Clin Dermatol 2004 Mar-Apr; 22 (2): 121-124
45. Ramos-Casals M, Nardi N, Lagrutta M, et al. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore) 2006 Mar; 85 (2): 95-104
46. Satirapoj B, Wongchinsri J, Youngprang N, et al. Predictors of renal involvement in patients with systemic lupus erythematosus. Asian Pac J Allergy Immunol 2007 Mar; 25 (1): 17-25
47. Alarcó n-Segovia D, Pé rez-Vá zquez ME, Villa AR, et al. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 1992 Apr; 21 (5): 275-286
48. Gó mez-Puerta JA, Martín H, Amigo MC, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore) 2005 Jul; 84 (4): 225-230
49. Kriseman YL, Nash JW,Hsu S. Criteria for the diagnosis of antiphospholipid syndrome in patients presenting with dermatologic symptoms. J Am Acad Dermatol 2007 Jul; 57 (1): 112-115
50. Sahin M, Duzgun N, Tunc SE, et al. Clinical manifestations and antiphosphatidylserine antibodies in patients with systemic lupus erythematosus: is there an association? Clin Rheumatol 2007 Feb; 26 (2): 154-160
51. Tebbe B, Hoffmann S, Orfanos CE. Course and prognosis of subacute cutaneous lupus erythematosus: a prospective study of 34 patients [in German]. Hautarzt 1994 Oct; 45 (10): 690-695
52. Weinstein C, Miller MH, Axtens R, et al. Lupus and non-lupus cutaneous manifestations in systemic lupus erythematosus. Aust N Z J Med 1987 Oct; 17 (5): 501-506 (Pubitemid 18028751)
53. Yell JA,Allen J, Wojnarowska F, et al. Bullous systemic lupus erythematosus: revised criteria for diagnosis. Br J Dermatol 1995 Jun; 132 (6): 921-928
54. Gammon WR, Briggaman RA. Bullous SLE: a phenotypically distinctive but immunologically heterogeneous bullous disorder. J Invest Dermatol 1993 Jan; 100 (1): 28S-34S
55. Burrows NP, Bhogal BS, Black MM, et al. Bullous eruption of systemic lupus erythematosus: a clinicopathological study of four cases. Br JDermatol 1993 Mar; 128 (3): 332-338
56. Tench CM, McCurdie I, White PD, et al. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology (Oxford) 2000 Nov; 39 (11): 1249-1254
57. Zoma A. Musculoskeletal involvement in systemic lupus erythematosus. Lupus 2004; 13 (11): 851-853
58. Gräfe A, Wollina U, Tebbe B, et al. Fibromyalgia in lupus erythematosus. Acta Derm Venereol 1999 Jan; 79 (1): 62-64
59. Björna¢dal L, Yin L, Granath F, et al. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-1995. J Rheumatol 2004 Apr; 31 (4): 713-719
60. Memet B, Ginzler EM. Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med 2007 Aug; 28 (4): 441-450
61. Boumpas DT, Austin 3rd HA, Fessler BJ, et al. Systemic lupus erythematosus: emerging concepts: part 1. Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 1995 Jun 15; 122 (12): 940-950
62. Parikh-Patel A, White RH, Allen M, et al. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control 2008 Oct; 19 (8): 887-894
63. Burnham TK, Fine G. The immunofluorescent ''band'' test for lupus erythematosus: 3. Employing clinically normal skin. Arch Dermatol 1971 Jan; 103 (1): 24-32
64. Font J, Cervera R, Navarro M, et al. Systemic lupus erythematosus in men: clinical and immunological characteristics. Ann Rheum Dis 1992 Sep; 51 (9): 1050-1052
65. Smith CD, Marino C,Rothfield NF. The clinical utility of the lupus band test. Arthritis Rheum 1984 Apr; 27 (4): 382-387
66. Cardinali C, Caproni M, Fabbri P. The utility of the lupus band test on sun-protected non-lesional skin for the diagnosis of systemic lupus erythematosus. Clin Exp Rheumatol 1999 Jul-Aug; 17 (4): 427-432
67. Olhoffer IH, Peng SL, Craft J. Revisiting autoantibody profiles in systemic lupus erythematosus. J Rheumatol 1997 Feb; 24 (2): 297-302
68. Ostrowski RA, Robinson JA. Antiphospholipid antibody syndrome and autoimmune diseases. HematolOncol Clin NorthAm2008 Feb; 22 (1): 53-65
69. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 2000 Jun; 42 (6): 983-987
70. Herzinger T, Plewig G, Röcken M. Use of sunscreens to protect against ultraviolet-induced lupus erythematosus. Arthritis Rheum 2004 Sep; 50 (9): 3045-3046
71. Jessop S, Whitelaw D, Jordaan F. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2001; (1): CD002954
72. Yoshimasu T, Ohtani T, Sakamoto T, et al. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 2002 Jan-Feb; 12 (1): 50-52
73. Kanekura T, Yoshii N, Terasaki K, et al. Efficacy of topical tacrolimus for treating themalar rash of systemic lupus erythematosus. Br JDermatol 2003 Feb; 148 (2): 353-356
74. Chambers CA. Topical tacrolimus for cutaneous lupus erythematosus. Br J Dermatol 2003 Apr; 148 (4): 829
75. Böhm M, Gaubitz M, Luger TA, et al. Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus: a report of three cases. Dermatology 2003; 207 (4): 381-385
76. Drüke A, Gambichler T, Altmeyer P, et al. 0.1% Tacrolimus ointment in a patient with subacute cutaneous lupus erythematosus. J Dermatolog Treat 2004 Jan; 15 (1): 63-64
77. Lampropoulos CE, Sangle S, Harrison P, et al. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) 2004 Nov; 43 (11): 1383-1385
78. Kreuter A, Gambichler T, Breuckmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004 Sep; 51 (3): 407-410
79. Tzellos TG, Kouvelas D. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. Eur J Clin Pharmacol 2008 Apr; 64 (4): 337-341
80. Tzung TY, Liu YS, Chang HW. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, doubleblind, bilateral comparison study. Br J Dermatol 2007 Jan; 156 (1): 191-192
81. Sugano M, Shintani Y, Kobayashi K, et al. Successful treatment with topical tacrolimus in four cases of discoid lupus erythematosus. J Dermatol 2006 Dec; 33 (12): 887-891
82. Sárdy M, Ruzicka T, Kuhn A. Topical calcineurin inhibitors in cutaneous lupus erythematosus. Arch Dermatol Res 2009 Jan; 301 (1): 93-98
83. Seiger E, Roland S, Goldman S. Cutaneous lupus treated with topical tretinoin: a case report. Cutis 1991 May; 47 (5): 351-355
84. Edwards KR, Burke WA. Treatment of localized discoid lupus erythematosus with tazarotene. J Am Acad Dermatol 1999 Dec; 41 (6): 1049-1050
85. Ruzicka T, Sommerburg C, Goerz G, et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992 Nov; 127 (5): 513-518
86. Toubi E, Rosner I, Rozenbaum M, et al. The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 2000; 9 (2): 92-95
87. Marmor MF, Carr RE, Easterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002 Jul; 109 (7): 1377-1382
88. Heath M, Raugi GJ. Evidence-based evaluation of immunomodulatory therapy for the cutaneousmanifestations of lupus. AdvDermatol 2004; 20: 257-291
89. Cuadrado MJ, Karim Y, Sanna G, et al. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med 2005 Mar; 118 (3): 246-250
90. Coelho A, Souto MI, Cardoso CR, et al. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients. Lupus 2005; 14 (6): 434-439
91. Wenzel J, Brähler S, Bauer R, et al. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol 2005 Jul; 153 (1): 157-162
92. Kuhn A, Specker C, Ruzicka T, et al. Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2002 Apr; 46 (4): 600-603
93. Sato EI. Methotrexate therapy in systemic lupus erythematosus. Lupus 2001; 10 (3): 162-164
94. Callen JP, Spencer LV, Burruss JB, et al. Azathioprine: an effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 1991 Apr; 127 (4): 515-522
95. Neri R, MoscaM, Bernacchi E, et al. A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with dapsone. Lupus 1999; 8 (3): 240-243
96. Yung A, Oakley A. Bullous systemic lupus erythematosus. Australas J Dermatol 2000 Nov; 41 (4): 234-237
97. Holtman JH, Neustadt DH, Klein J, et al. Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2 deficiency. J Rheumatol 1990 Sep; 17 (9): 1222-1225
98. Camisa C. Vesiculobullous systemic lupus erythematosus: a report of four cases. J Am Acad Dermatol 1988 Jan; 18 (1 Pt 1): 93-100
99. Lindskov R, Reymann F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica 1986; 172 (4): 214-217
100. McCormack LS, Elgart ML, Turner ML. Annular subacute cutaneous lupus erythematosus responsive to dapsone. JAmAcad Dermatol 1984 Sep; 11 (3): 397-401
101. Fenton DA, Black MM. Low-dose dapsone in the treatment of subacute cutaneous lupus erythematosus. Clin Exp Dermatol 1986 Jan; 11 (1): 102-103
102. Hall RP, Lawley TJ, Smith HR, et al. Bullous eruption of systemic lupus erythematosus: dramatic response to dapsone therapy. Ann Intern Med 1982 Aug; 97 (2): 165-170
103. Ujiie H, Shimizu T, Ito M, et al. Lupus erythematosus profundus successfully treated with dapsone: review of the literature. Arch Dermatol 2006 Mar; 142 (3): 399-401
104. Coburn PR, Shuster S. Dapsone and discoid lupus erythematosus. Br J Dermatol 1982 Jan; 106 (1): 105-106
105. Bezerra EL, Vilar MJ, da Trindade Neto PB, et al. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum 2005 Oct; 52 (10): 3073-3078
106. Wozniacka A, Salamon M, Lesiak A, et al. The dynamism of cutaneous lupus erythematosus: mild discoid lupus erythematosus evolving into SLE with SCLE and treatment-resistant lupus panniculitis. Clin Rheumatol 2007 Jul; 26 (7): 1176-1179
107. Saeki Y, Ohshima S, Kurimoto I, et al. Maintaining remission of lupus erythematosus profundus (LEP) with cyclosporin A. Lupus 2000; 9 (5): 390-392
108. Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003 Jan; 48 (1): 166-173
109. Wenzel J, Bieber T, Uerlich M, et al. Systemic treatment of cutaneous lupus erythematosus [in German]. J Dtsch Dermatol Ges 2003 Sep; 1 (9): 694-704
110. Newton RC, Jorizzo JL, Solomon Jr AR, et al. Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. Arch Dermatol 1986 Feb; 122 (2): 170-176
111. Furner BB. Subacute cutaneous lupus erythematosus response to isotretinoin. Int J Dermatol 1990 Oct; 29 (8): 587-590
112. Vena GA, Coviello C, Angelini G. Use of oral isotretinoin in the treatment of cutaneous lupus erythematosus [in Italian]. G Ital Dermatol Venereol 1989 Jun; 124 (6): 311-315
113. Shornick JK, Formica N, Parke AL. Isotretinoin for refractory lupus erythematosus. J Am Acad Dermatol 1991 Jan; 24 (1): 49-52
114. Green SG, Piette WW. Successful treatment of hypertrophic lupus erythematosus with isotretinoin. J AmAcad Dermatol 1987 Aug; 17 (2 Pt 2): 364-368
115. Rubenstein DJ, Huntley AC. Keratotic lupus erythematosus: treatment with isotretinoin. J Am Acad Dermatol 1986 May; 14 (5 Pt 2): 910-914
116. Al-Mutairi N, Rijhwani M, Nour-Eldin O. Hypertrophic lupus erythematosus treated successfullywith acitretin asmonotherapy. J Dermatol 2005 Jun; 32 (6): 482-486
117. Ruzicka T, Meurer M, Bieber T. Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Arch Dermatol 1988 Jun; 124 (6): 897-902
118. Duna GF, Cash JM. Treatment of refractory cutaneous lupus erythematosus. Rheum Dis Clin North Am 1995 Feb; 21 (1): 99-115
119. Schanz S, Ulmer A, Rassner G, et al. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br JDermatol 2002 Jul; 147 (1): 174-178
120. Pisoni CN, Obermoser G, Cuadrado MJ, et al. Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol 2005 May-Jun; 23 (3): 393-396
121. Mok CC. Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review. Scand J Rheumatol 2007 Sep-Oct; 36 (5): 329-337
122. Usmani N, Goodfield M. Efalizumab in the treatment of discoid lupus erythematosus. Arch Dermatol 2007 Jul; 143 (7): 873-877
123. Hamprecht A, Tüting T, Bieber T, et al. Successful treatment of recalcitrant malar rash in a patient with cutaneous lupus erythematosus with efalizumab. Clin Exp Dermatol 2008 May; 33 (3): 347-348
124. Clayton TH, Ogden S, Goodfield MD. Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab. J Am Acad Dermatol 2006 May; 54 (5): 892-895
125. Bentley DD, Graves JE, Smith DI, et al. Efalizumab-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2006 May; 54 (5 Suppl.): S242-36
126. Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol 2006 Mar; 54 (3 Suppl. 2): S139-42
127. Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to antitumor necrosis factor alpha agents. Semin Arthritis Rheum 2008 Jun; 37 (6): 381-387
128. Sheth N, Greenblatt D, Patel S, et al. Adalimumab-induced cutaneous lupus. Clin Exp Dermatol 2007 Sep; 32 (5): 593-594
129. Ramos-Casals M, Brito-Zeró n P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007 Jul; 86 (4): 242-251
130. Goodfield M, Davison K, Bowden K. Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat 2004 Jan; 15 (1): 46-50
131. Lampropoulos CE, Hughes GR, D'Cruz DP. Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative. Clin Rheumatol 2007 Jun; 26 (6): 981-983
132. Kreuter A, Hyun J, Altmeyer P, et al. Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus. Acta Derm Venereol 2005; 85 (6): 545-547
133. Uthman I, Taher A, Abbas O, et al. Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case. Dermatology 2008; 216 (3): 257-259
134. Gordon C, Wallace DJ, Shinada S, et al. Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus. Rheumatology (Oxford) 2008 Mar; 47 (3): 334-338
135. Wenzel J, Zahn S, Bieber T, et al. Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus. Arch Dermatol Res 2009 Jan; 301 (1): 83-86
136. Meller S, Winterberg F, Gilliet M, et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 2005 May; 52 (5): 1504-1516
137. Ho V, Mclean A, Terry S. Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C. J Clin Rheumatol 2008 Jun; 14 (3): 166-168
138. Crispín JC, Díaz-Jouanen E. Systemic lupus erythematosus induced by therapy with interferon-beta in a patient with multiple sclerosis. Lupus 2005; 14 (6): 495-496
139. Flores A, Olivé A, Feliu E, et al. Systemic lupus erythematosus following interferon therapy [letter]. Br J Rheumatol 1994 Aug; 33 (8): 787